A comparative study of three different doses of nalbuphine as an adjuvant to bupivacaine in suprascapular nerve block for postoperative analgesia in arthroscopic shoulder surgery

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202001596903715

Enrollment

Registered

2020-01-13

Start date

2019-12-23

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia

Interventions

suprascapular nerve block

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ASA physical status I-IIl

Exclusion criteria

Exclusion criteria: obesity , allergy to local anesthetic, coagulopathy presence of infection at the site of the block.

Design outcomes

Primary

Measure	Time frame
result related to the VAS score	—

Secondary

Measure	Time frame
: side effects (nausea and vomiting),additional analgesic requirements,and Ramsey Sedation Scores (RSS) will recorded. RSS>or= 5 will considered excessive sedation	—

Countries

Egypt

Contacts

Public Contactnoha afify

lecturer in anesthesiology department

nohaafify2014@gmail.com01069113014

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026